How wargaming was used to understand the likely future HCV landscape and give strategies for brand success
Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of development of both our client’s product and the competitors, a number of different scenarios could have played out. Consequently, the company wanted to conduct research in order to feed into strategy development for their product. What would physicians think of the new entrants and how could this be leveraged to ensure a successful launch?
Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C.
The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.
Therapy Watch HCV expands into 4 additional EU markets
The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space of time; from treating the disease to effectively curing it. With further products scheduled to come into the market in the next 6 months, it is becoming an increasingly competitive market.
As of September 2016 Therapy Watch HCV will be adding the 4 additional EU markets of Austria, Portugal, Switzerland & Sweden to our existing EU HCV tracker, which already covers the 5 markets of France, Germany, Italy, Spain and the UK. In these EU5 markets we currently interview 50 specialists, collecting 7 dynamic and 7 total records from each with 700 PRFs in each market per quarter. In the 4 smaller additional European markets we will be interviewing 15 physicians per quarter, with each completing 5 dynamic and 5 total records.
Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America
Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.
If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.
During the course of my working life, hepatitis C is one of the therapy areas in which I have seen the most dramatic advances in terms of treatment. It is definitely one of pharma’s success stories. It has experienced rapid evolution from interferon- and ribavirin-based treatment in 1998, through pegylated interferon-based regimens and protease inhibitors and on to the recent wave of direct-acting antiviral therapies available today. It would not be an exaggeration to say that these interferon-free treatment regimens, with high efficacy (Sustained Virological Response (SVR) rates approaching 100%), minimal side effects and short treatment durations, have the potential to revolutionize the treatment of hepatitis C.
HCV LATAM infographic
Hepatitis C virus (HCV) is well recognised as a worldwide problem with approximately 150 million chronic carriers. If left untreated HCV becomes a chronic health problem putting a huge strain on national healthcare resources. Within Latin America studies suggest that around 4.6 million people are currently infected with chronic HCV.
Click here to view our latest infographic, in which we provide an introduction to the HCV LATAM patient.
Find out more about our experience in emerging markets »
Sign up to receive Rapport Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »